Akèy › Kansè pwostat › South Carolina › Myrtle Beach
Etid klinik pou Kansè pwostat nan Myrtle Beach, SC
24 etid pou Kansè pwostat ap chèche patisipan nan sit nan ak bò kote Myrtle Beach (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
A Study to Learn About the Investigational Drug Rinzimetostat (ORIC-944) in Patients With mCRPC Who Were Previously Treated With Abiraterone Acetate (Himalayas-1)
Ap rekriteFaz 3
- Carolina Urologic Research Center, Myrtle Beach
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
- MUSC Hematology-Oncology at Murrells Inlet, Murrells Inlet · 13 mi lwen
Prostate Cancer Risk Identification in a Multi-Ethnic Cohort: a Prospective US-based Multi-center Validation Study of Proclarix
Ap rekriteEtid obsèvasyon
- Carolina Urologic Research Center, Myrtle Beach
Phase 1 Study of ACE-232 to Treat Patients With Metastatic Castration-Resistant Prostate Cancer
Ap rekriteFaz 1
- Carolina Urologic Research Center, Myrtle Beach
Study of HLD-0915 (JNJ-101556143) in Patients With Metastatic Prostate Cancer
Ap rekriteFaz 1/2
- Carolina Urologic Research Center, Myrtle Beach
Study of AZD0516 as Monotherapy and in Combination in Participants With Metastatic Prostate Cancer
Ap rekriteFaz 1/2
- Research Site, Myrtle Beach
This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.
Ap rekriteFaz 3
- Grand Strand Medical Center, Myrtle Beach
- Carolina Urologic Research Center, LLC, Myrtle Beach
- Parkway Surgery Center, Myrtle Beach
A Study in Patients With Metastatic Castration-Resistant Prostate Cancer
Ap rekriteFaz 1
- START Carolinas, Myrtle Beach
Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy
Ap rekriteFaz 2/3
- Carolina Urologic Research Center, Myrtle Beach
A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
Ap rekriteFaz 3
- South Texas Accelerated Research Therapeutics - Carolinas, Myrtle Beach
Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC
Ap rekriteFaz 3
- Carolina Urologic Research Center, Myrtle Beach
A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation
Ap rekriteFaz 3
- Research Site, Myrtle Beach
A Biomarker Study in Men With Localized Prostate Cancer Treated With Aglatimagene Besadenovec
Ap rekriteFaz 2
- START Carolinas, Myrtle Beach
Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy
Ap rekriteFaz 3
- Carolina Urologic Research Center, Myrtle Beach
A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer
Ap rekriteFaz 2
- Carolina Urologic Research Center, Myrtle Beach
AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)
Ap rekriteFaz 3
- Research Site, Myrtle Beach
A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Ap rekriteFaz 2
- Carolina Urologic Research Center, Myrtle Beach
Evaluation of Neoadjuvant Xaluritamig in Localized Prostate Cancer
Ap rekriteFaz 1
- Carolina Urologic Research Center, Myrtle Beach
PSMA PET Combined With MRI for the Detection of PCa
Ap rekriteFaz 3Volontè an sante akeyi
- Atlantic Urology Specialists, Myrtle Beach
A Clinical Study of KTX-2001 in Subjects With Metastatic Castration-Resistant Prostate Cancer (STRIKE-001)
Ap rekriteFaz 1
- Carolina Urologic Research Center, the START Center for Cancer Research, Myrtle Beach
Study Evaluating the Safety, Tolerability, and Efficacy of Xaluritamig in Combination With Androgen Receptor Pathway Inhibitors in Participants With Metastatic Hormone-sensitive Prostate Cancer
Ap rekriteFaz 1
- South Texas Accelerated Research Therapeutics - Carolinas, Myrtle Beach
A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer
Ap rekriteFaz 1
- Carolina Urologic Research Center, Myrtle Beach
Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer
Ap rekriteFaz 3
- Carolina Regional Cancer Center, Myrtle Beach
FK-PC101 as Adjuvant Therapy for Men With High-Risk Prostate Cancer
Ap rekriteFaz 2
- Carolina Urologic Research Center, Myrtle Beach
Etid Kansè pwostat nan lòt vil
- New York City, NY103 etid
- Houston, TX76 etid
- Los Angeles, CA61 etid
- Boston, MA59 etid
- St. Louis, MO46 etid
- Chicago, IL45 etid
- San Francisco, CA45 etid
- Philadelphia, PA44 etid
- Baltimore, MD43 etid
- Nashville, TN43 etid
- Seattle, WA42 etid
- Washington, DC38 etid
Lòt etid nan Myrtle Beach
- Kansè vejik10 etid
- Kansè Vezik ki pa envazif miskilè9 etid
- Kansè renn (Kasinom selil renn)6 etid
- Kasinom Selil Transizyonèl (Urotelyal)5 etid
- Kansè Metastatik5 etid
- Dyabèt Tip 23 etid
- Kansè pwostat rezistan a kastasyon3 etid
- Kansè (tout kalite)3 etid
- Kasinom in situ3 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.